Navigation Links
Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Date:10/25/2007

PLYMOUTH MEETING, Pa., Oct. 25 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) is providing the following summary of highlights related to the successful first Phase 1 study of trodusquemine and additional preclinical data expanding the support for selectivity and specificity of the drug in preclinical models from the North American Association for the Study of Obesity (NAASO) Annual Meeting in New Orleans:

-- Interim results from Study MSI-1436C-101 presented at Genaera's poster

session, "First in Human Use of MSI-1436 (Trodusquemine), a Centrally

and Peripherally Acting Selective PTP1B Inhibitor," demonstrated that

the drug was safe and well tolerated by the healthy, overweight and

obese volunteers at doses well above the anticipated therapeutic dose

level with no evidence of serious adverse events. No pharmacodynamic

effects were anticipated or observed in this study with a single dose

of MSI-1436.

-- There were no significant changes in vital signs, cardiovascular

parameters (as assessed by ECG and cardiac telemetry), clinical

laboratory or hematology parameters. Moreover, pharmacokinetic (PK)

profiles of trodusquemine in the first five cohorts of the study showed

a consistent pattern with minimal subject-to-subject variability and

linearity was observed across the range of doses studied. Values for a

wide range of endocrine and metabolic biomarkers as well as evaluations

of mood and cognition were also found to be stable across the subjects

receiving all levels of the drug or placebo during the trial.

-- Consequently, these positive Study MSI-1436C
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. XTL Provides Update on Phase I Clinical Trial of XTL-2125
11. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
(Date:8/21/2014)... /PRNewswire-iReach/ -- Inc. magazine today ranked ... straight year, No. 349 in Health on its ... the nation,s fastest-growing private companies. The list represents ... segment of the economy—America,s independent entrepreneurs. Companies such ... Zillow, and many other well-known names gained early ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... DIEGO, Jan. 10, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Linda Amper, Ph.D., as Senior Vice President of Human ... Economics & Outcomes Research (HEOR), and John Womelsdorf, Ph.D., ... will strengthen the management team as the Company prepares ...
... Calif., Jan. 10, 2011 OncoMed Pharmaceuticals, Inc., ... today announced that patient dosing has commenced in a Phase ... tumor cancers.   OMP-59R5 is a monoclonal antibody ... to specifically block these targets to enter human studies.  The ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Key Additions to Management Team 2Optimer Pharmaceuticals Announces Key Additions to Management Team 3Optimer Pharmaceuticals Announces Key Additions to Management Team 4OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 2OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 3
(Date:8/22/2014)... patients who need surgery for facial pain caused by ... often used, reports a study in the September issue ... the Congress of Neurological Surgeons . The journal ... a part of Wolters Kluwer Health . , ... much lower cost than other types of surgical treatments ...
(Date:8/22/2014)... August 22, 2014 “Dr. Luciana Show – ... , aka Dr. Luciana, is finding it challenging to stay ... while taking care of hundreds of students, so the editing ... the show is completed, and she recently entered it into ... including those of her husband, actor/screenwriter Gregory Graham , ...
(Date:8/22/2014)... 22, 2014 The report "Higher ... Security & Compliance, Campus Technology, Student & Curriculum, ... (2014-2019)", defines and segments the global Higher Ed ... and forecasting of market sizes. The report also ... and opportunities impacting it along with the adoption ...
(Date:8/22/2014)... However, these are two entirely different mechanisms that occur ... digest lactose properly because they lack an enzyme known ... more dangerous cow milk allergy, however, the body,s immune ... , According to statistics, about two to three percent ... allergy. Less adults are diagnosed with the disease. The ...
(Date:8/22/2014)... August 22, 2014 This funding was ... research affiliate, Saneron CCEL Therapeutics, Inc. in the form ... is extremely pleased to collaborate with Saneron on several ... we hope will lead to regenerative therapies using ... as ALS,” David Portnoy, Chairman and Co-CEO of Cryo-Cell, ...
Breaking Medicine News(10 mins):Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3
... psoriasis condition are more likely to smoke, and smoking contributes ... scaling of the skin, and affect places like legs, scalp, ... of the feet. The chances of people with psoriasis suffering ... published in the Archives of Dermatology. ,Data ...
... Co, known as MSD India, has entered into a collaboration ... studies on the former's investigational cervical cancer drug, Gardasil.// ... India. Under the agreement, clinical trials will be conducted for ... ,The vaccine that has been developed by Merck and ...
... Rutgers, The State University of New Jersey have come ... related to determining the quality of mate in humans.// ... in choosing mates among many animal species. Impressive dancers ... ,Rutgers in association with computer scientist at the University ...
... sitting or lying down is a treatable health problem, but ... ,The condition, called Restless Legs Syndrome (RLS), makes it ... long drives or even while watching a movie, say experts., ... which is accompanied in many cases by a tingling and ...
... Department of Health and Mental Hygiene (DOHMH) has banned at ... "dangerous levels" of lead and mercury. // , ,"Though ... Board of the Institute of Medicine of the National Academies ... ppm (parts per million) of lead and no more than ...
... we took note and took care of mother nature. ... USA.,It is called the Canon National Parks Science Scholars ... eight doctoral students -- from Canada to Chile, and ... are receiving significant multi-year scholarships this year to conduct ...
Cached Medicine News:Health News:Merck, ICMR to conduct joint trials on cervical cancer vaccine 2Health News:Shaking Legs Syndrome Is Curable 2Health News:NY Health Dept Bans 3 Ayurveda Drugs 2Health News:Time to wake up as conservationists 2Health News:Time to wake up as conservationists 3
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
Angled 45 degrees, 10 mm shaft with 0.2 mm tip. Round knurled handle with dull finish. Overall length: 4.6 inches....
Straight 31 mm shaft with flat handle and polished finish. 0.5 mm cup. Overall length: 5 inches....
0.5 mm curette cup, reverse side of sandblasted to polish capsule. Round knurled handle with polished finish. Overall length: 5 inches....
Medicine Products: